Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Noriko Fukuhara,Won Seog Kim,Dok Hyun Yoon,Eiju Negoro,Kazuhito Yamamoto,Toshiki Uchida,Koji Izutsu,Yasuhito Terui,Hideaki Nakajima,Kiyoshi Ando,Youko Suehiro,Hye Jin Kang,Po-Shen Ko,Fumiko Nagahama,Yusuke Sonehara,Hirokazu Nagai,Hwei-Fang Tien,Yok-Lam Kwong,Kensei Tobinai

Blood（2021）

引用 3|浏览4

暂无评分

摘要

Background: Darinaparsin is a novel organic arsenic compound composed of dimethylated arsenic linked to glutathione. In two phase I studies including Japanese and Korean patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), darinaparsin was well tolerated and demonstrated potential efficacy (ASH2015 Abstract #2714 and Jpn J Clin Oncol. 2021, 51:218). The efficacy, safety and pharmacokinetics of darinaparsin in Asian patients with relapsed or refractory PTCL were evaluated in a multinational phase II study.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要